# GPT 5.2 Review - Reviewer 2/3 (Parallel)

**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Reasoning effort:** medium
**Timestamp:** 2026-01-23T22:11:27.056494
**Review mode:** Parallel (3 independent reviewers)
**Response ID:** resp_00f5c34d2b3f22d0006973e357ccf88193a346d7f694cfc089
**Tokens:** 9734 in / 4810 out
**Response SHA256:** fa38c24096cc637e

---

## Referee report (top general-interest / AEJ: Economic Policy standard)

### Summary
The paper asks whether **PDMP mandatory-query mandates** reduce **opioid overdose mortality**, using CDC VSRR mortality data (2015–2020) and staggered-adoption DiD (TWFE and Sun–Abraham). The headline result is **statistically null** (TWFE: +2.0% SE 5.8%; Sun–Abraham ATT: −2.5% SE 2.8%). The paper is admirably transparent about **data limitations** (mortality series starts in 2015, making 2012–2015 adopters “always treated”) and about **pre-trend violations** in the event study.

At a top journal standard, however, the current design does **not deliver credible identification**, and the “null” result is not interpretable as evidence of no effect. The paper reads closer to a careful class/working-paper exercise documenting why this specific dataset/time window cannot answer the causal question, rather than a publishable causal evaluation.

---

# 1. FORMAT CHECK

### Length
- **Fails top-journal norm.** The excerpt provided is **~19 pages** (page numbers shown through ~19 including figures/references). Top general-interest journals typically require a main text of at least ~25 pages to develop motivation, institutional detail, validation, robustness, and interpretation. Even for AEJ: Policy, this is short given the identification challenges you acknowledge.

### References
- **Thin for modern DiD and for opioid-policy empirics.** You cite Sun–Abraham and Goodman-Bacon and a few PDMP papers, but the bibliography is not yet adequate for a top field/general journal (details in Section 4 below).

### Prose (paragraph form vs bullets)
- Mostly paragraphs, but **Section 5** (“Discussion and Conclusion”) contains a **numbered bullet list** of key findings. Bullet summaries are fine, but at top-journal standards the discussion/conclusion should be primarily **integrated prose** with interpretation and mechanisms.

### Section depth (3+ substantive paragraphs each)
- **Introduction:** ~3 paragraphs—OK but still thin on contribution/novelty and why prior work is unsettled.
- **Data:** reasonably detailed.
- **Empirical Strategy:** OK structurally, but missing key design choices and diagnostics (see below).
- **Results/Discussion:** too brief relative to the identification fragility you uncover. A top-journal paper would typically add (i) richer institutional/policy variation, (ii) multiple outcome definitions, (iii) validation using prescribing outcomes, (iv) alternative designs.

### Figures
- Figures shown have axes and plotted data. However:
  - **Legibility**: fonts/axis labels look small in the provided renderings (esp. map and cohort-trend plot).
  - The event-study figure would benefit from explicit y-axis units (“log points”) and a horizontal 0 line labeled.

### Tables
- Tables contain real numbers and notes—good. Table 3 reports SEs and sample sizes—good.

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

### (a) Standard errors
- **Pass**: Table 3 reports SEs in parentheses; event-study SEs/p-values are discussed.

### (b) Significance testing
- **Pass**: p-values are reported in text and stars appear in table notes (though no stars are shown because estimates are insignificant).

### (c) Confidence intervals
- **Partially fails best practice**: You show 95% CIs in the event-study figure (good), but **main tables do not report 95% CIs**. Top-journal expectation: report **CI for the main ATT/TWFE** in Table 3 and interpret magnitudes (e.g., “rule out decreases larger than X%”).

### (d) Sample sizes
- **Pass**: You report observations and jurisdictions for TWFE and Sun–Abraham.

### (e) DiD with staggered adoption
- **Borderline / not sufficient for publication as-is.**
  - You correctly note TWFE problems and implement **Sun–Abraham** (good).
  - But your **effective identifying variation is extremely limited**: only **20 later adopters** with complete pre-periods in Sun–Abraham, compared to **7 never-treated**. This is not merely a power issue; it raises design fragility and comparability concerns.
  - You do **not** implement **Callaway & Sant’Anna** (never-treated / not-yet-treated group-time ATTs), **de Chaisemartin & D’Haultfoeuille**, or **imputation estimators**; nor do you show that results are robust across these estimators. At top-journal standards, Sun–Abraham alone is not enough.

### Inference quality / small number of clusters
- With ~27 or 41 clusters (jurisdictions), conventional clustered SEs may be acceptable, but best practice—especially with only **7 never-treated**—is to include **wild cluster bootstrap** p-values and/or **randomization inference / permutation** checks.
- Given staggered adoption and few effective control units, you should also report **sensitivity of p-values** to alternative clustering (e.g., two-way clustering by state and year is not feasible here, but wild bootstrap is).

**Bottom line on methodology:** you clear the *minimum* inference bar, but not the *top-journal* bar for robustness and estimator triangulation in staggered DiD.

---

# 3. IDENTIFICATION STRATEGY

### Core issue: the design does not credibly identify the causal effect
You are explicit that data begin in 2015, making 2012–2015 adopters always-treated. This creates several identification failures:

1. **Early adopters are systematically different** (high baseline mortality, different epidemic phase), yet they contribute heavily to TWFE post-treatment variation without pre-trends.
2. **Later adopters are compared to a small “never-treated” set** (AK, CA, CO, DC, MI, MO, MT). Those jurisdictions are plausibly non-comparable on many dimensions (urbanization, fentanyl penetration timing, PDMP baseline strength, healthcare markets, policy packages).
3. Your event study shows **statistically significant pre-trends** (t = −3 significant at p = 0.007; Section 4.2 / Figure 1). This directly undermines the central identifying assumption. In a top-journal setting, this is close to a knockout unless you can (i) repair identification or (ii) reframe the estimand.

### Placebos and robustness
- The robustness section is thin: examining opioid share of overdoses is not a compelling placebo because policy can affect both numerator and denominator.
- Missing are:
  - **Negative control outcomes** plausibly unaffected by PDMP mandates (e.g., non-drug mortality, deaths from causes unrelated to prescribing).
  - **Policy-placebo timing** (assign fake adoption dates to never-treated, test distribution of placebo effects).
  - **Pre-trend sensitivity methods** (see Rambachan–Roth; also “honest DiD” bounds).
  - **Alternative outcome construction**: rates per 100k; age-adjusted mortality; separating prescription opioids vs synthetic opioids (fentanyl) vs heroin.

### Treatment coding and timing
You code mid-year effective dates as treated for the entire calendar year and acknowledge attenuation (Section 5; Appendix notes). This is not a minor detail:
- If the first treated year contains mostly untreated months (e.g., Ohio effective Dec 1, 2015; Texas Sep 1, 2019), this is **systematic measurement error in treatment**, likely biasing effects toward zero and distorting event-time dynamics.

A top-journal version must either:
- Use **monthly** outcomes and monthly policy timing; or
- Code treatment intensity as fraction-of-year treated; or
- Exclude the “partial exposure” year and define first treated year as the first full calendar year after implementation (with sensitivity checks).

### Endogeneity / policy packages
You mention endogenous adoption. But you do not incorporate:
- Other opioid policies adopted concurrently (pill mill laws, naloxone access, Medicaid expansion, pain clinic regulations, prescribing limits).
- Differential fentanyl penetration and supply shocks (a huge confounder post-2014).

Without controlling for policy bundles or modeling epidemic phase, the DiD is very likely confounded.

**Conclusion on identification:** As written, the paper does not support causal claims. The correct interpretation is closer to: “Using VSRR 2015–2020 and this mandate coding, we cannot credibly estimate the effect.”

---

# 4. LITERATURE (missing references + BibTeX)

### Methodology you should cite and engage
You cite Sun–Abraham and Goodman-Bacon, but a top-journal paper in 2026 must situate itself in the modern DiD canon and sensitivity literature:

1) **Callaway & Sant’Anna (group-time ATT, never/not-yet treated comparisons)**
```bibtex
@article{CallawaySantAnna2021,
  author = {Callaway, Brantly and Sant'Anna, Pedro H. C.},
  title = {Difference-in-Differences with Multiple Time Periods},
  journal = {Journal of Econometrics},
  year = {2021},
  volume = {225},
  number = {2},
  pages = {200--230}
}
```

2) **de Chaisemartin & D’Haultfoeuille (TWFE can be badly biased under heterogeneity)**
```bibtex
@article{deChaisemartinDHaultfoeuille2020,
  author = {de Chaisemartin, Cl{\'e}ment and d'Haultf{\oe}uille, Xavier},
  title = {Two-Way Fixed Effects Estimators with Heterogeneous Treatment Effects},
  journal = {American Economic Review},
  year = {2020},
  volume = {110},
  number = {9},
  pages = {2964--2996}
}
```

3) **Rambachan & Roth (credible pretrend deviations / “honest DiD”)**
```bibtex
@article{RambachanRoth2023,
  author = {Rambachan, Ashesh and Roth, Jonathan},
  title = {A More Credible Approach to Parallel Trends},
  journal = {Review of Economic Studies},
  year = {2023},
  volume = {90},
  number = {5},
  pages = {2555--2591}
}
```

4) **(Optional but recommended) Borusyak–Jaravel–Spiess imputation/event-study robustness**
If you use it, cite the published version if available; otherwise cite as working paper/NBER.
```bibtex
@techreport{BorusyakJaravelSpiess2021,
  author = {Borusyak, Kirill and Jaravel, Xavier and Spiess, Jann},
  title = {Revisiting Event Study Designs: Robust and Efficient Estimation},
  institution = {NBER Working Paper},
  year = {2021},
  number = {28252}
}
```

### Policy/domain literature gaps
Your domain citations are selective. A top-journal piece needs to engage more comprehensively with PDMP evidence and opioid policy substitution:

- More empirical PDMP work beyond Buchmueller–Carey and Patrick et al. (e.g., effects on prescribing, illicit substitution, heterogeneous impacts).
- Work on fentanyl-driven mortality and the structural break around 2013–2016 (important for parallel trends plausibility).
- Policy evaluation papers on naloxone access laws, pain clinic laws, prescribing limits, Medicaid expansion and opioid mortality—because they are confounders and/or interacting policies.

At minimum, you should add and discuss several major opioid-policy evaluation papers (AEJ:EP, JHE, Health Affairs, etc.). The paper currently reads under-cited for the breadth of the claim.

### Positioning / contribution
Right now, the contribution is essentially: “We tried modern staggered DiD on 2015–2020 VSRR and got null + pretrend violations.” That is not enough for AER/QJE/JPE/ReStud/Ecta/AEJ:EP unless you (i) solve the identification problem or (ii) reframe as a methodological/data cautionary paper with broader lessons validated across multiple policies/datasets.

---

# 5. WRITING QUALITY (CRITICAL)

### Prose vs bullets
- Mostly fine, but **Section 5** relies on a numbered list for key conclusions. Top journals typically expect richer narrative synthesis and interpretation in prose (lists are acceptable but should not substitute for discussion).

### Narrative flow
- The intro motivates the question but does not deliver a compelling “why now / why this paper changes what we know” arc.
- The paper’s *true* “result” is that the dataset/time window cannot support credible DiD due to always-treated cohorts and pretrends. That could be compelling, but you need to **own that framing** and build the narrative around *diagnosing failure modes* rather than presenting the null estimate as the headline.

### Accessibility and interpretation
- You report percent effects, SEs, and some p-values. But you do not sufficiently:
  - Translate log-point effects into **lives** (back-of-envelope) or into **deaths per 100k**.
  - Provide **CI-based interpretation** (“we can rule out reductions larger than X%”).

### Tables/figures as standalone
- Notes are decent. Figures need improved legibility and more explicit axis/units.

---

# 6. CONSTRUCTIVE SUGGESTIONS (how to make it publishable)

## A. Fix the outcome construction (this is essential)
1) Use **mortality rates** (per 100k) and preferably **age-adjusted** opioid mortality (CDC WONDER / NVSS final multiple-cause-of-death data), not raw counts. Counts mechanically load on population size and change over time.
2) Separate opioid deaths into at least:
   - **Prescription opioids (natural/semi-synthetic, methadone)** vs
   - **Heroin** vs
   - **Synthetic opioids (fentanyl)**  
   PDMP mandates plausibly reduce prescription opioid availability but may increase illicit substitution; aggregating obscures mechanisms.

## B. Fix treatment timing and measurement error
- Move to **monthly** mortality (VSRR is monthly by construction) and code the mandate **by effective month**. This alone could materially change event-study dynamics and attenuation.
- Alternatively, code fraction-of-year treated and test sensitivity.

## C. Use multiple staggered-DiD estimators and diagnostics
At minimum include:
- **Callaway & Sant’Anna** group-time ATT with never-treated as controls; also show results using not-yet-treated where feasible.
- **Imputation estimator** (Borusyak–Jaravel–Spiess) as robustness.
- **de Chaisemartin–D’Haultfoeuille** style decomposition or diagnostics on TWFE weights.

## D. Address pre-trends explicitly rather than merely “noting” them
- Implement **Rambachan–Roth “honest DiD” bounds** (or similar sensitivity) to show what conclusions survive plausible deviations from parallel trends.
- Consider adding **state-specific linear trends** *only as a sensitivity check* (not as a panacea). If results hinge on trends, say so.

## E. Enrich the identification or reframe the paper
Right now, the paper is stuck: limited pre-period + endogenous adoption + heterogeneous epidemic timing. To become publishable, you need a stronger design:
- **Synthetic control / augmented synthetic control** for a subset of states with clean timing and long pre-periods (requires earlier mortality series).
- Instrumental-variable strategies are hard here, but you could explore **political/institutional predictors** of mandate adoption that are plausibly orthogonal to contemporaneous mortality shocks (this is challenging and must be defended).
- Alternatively, reframe as a **methods/data paper**: show systematically (across multiple opioid policies, not just PDMP mandates) how VSRR starting in 2015 plus staggered adoption creates misleading TWFE/Sun–Abraham inference. That would require broader scope than the current single-policy evaluation.

## F. Control for concurrent policies / epidemic phase
At minimum, incorporate controls or policy indicators for:
- naloxone access laws, Good Samaritan laws,
- prescribing limits,
- pain clinic / pill mill laws,
- Medicaid expansion,
- opioid settlement funds timing is later, but other harm reduction policies matter,
and/or interact effects by pre-period prescription opioid intensity and fentanyl penetration.

---

# 7. OVERALL ASSESSMENT

### Strengths
- Transparent about sample construction, always-treated cohorts, and estimator limitations.
- Uses Sun–Abraham rather than relying solely on TWFE.
- Clearly communicates that pre-trends are present (Figure 1 / Section 4.2).

### Critical weaknesses (blocking for publication)
1. **Identification failure**: significant pre-trends and non-comparable controls make causal claims untenable.
2. **Severe treatment timing mismeasurement** (annual coding with mid/late-year implementation) likely attenuates effects and distorts dynamics.
3. **Outcome choice** (counts, not rates; aggregates across opioid types) is not aligned with PDMP mechanism and introduces confounds.
4. **Literature positioning** is incomplete for modern DiD and opioid policy evaluation.
5. **Contribution is currently negative/inconclusive** without either a stronger design or a reframing as a broader methodological cautionary piece.

---

DECISION: REJECT AND RESUBMIT